1. Agusti A, Chen R, Criner G, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. Global Initiative for Chronic Obstructive Lung Disease; 2018.

2. Wheaton AG, Cunningham TJ, Ford ES, Croft JB; Centers for Disease Control and Prevention (CDC). Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013. MMWR Morb MortalWkly Rep. 2015;64(11):289-295.

3. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143(5):1395-1406. doi:10.1378/chest.12-1135

4. Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017;(293):1-8.

5. Yawn B, Kim V. COPD in primary care: key considerations for optimized management: treatment options for stable chronic obstructive pulmonary disease: current recommendations and unmet needs. J Fam Pract. 2018;67(2)(suppl):S28-S37.

6. ZuWallack R. How are you doing? what are you doing? differing perspectives in the assessment of individuals with COPD. COPD. 2007;4(3):293-297.doi:10.1080/15412550701480620

7. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic bstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704-711. doi:10.1016/S0140-6736(09)61301-5

8. Mahler DA,Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580-586. doi:10.1378/chest.93.3.580

9. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009; 34(3):648-654. doi:10.1183/09031936.00102509

10. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873-884. doi:10.1183/09031936.00025214

11. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374(9691):733-743. doi:10.1016/S0140-6736(09) 61303-9

12. Krishnan JK, Martinez FJ. Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps. Curr Opin Pulm Med. 2018;24(2):124-129. doi:10.1097/MCP.0000000000000456

13. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935-945. doi:10.1016/S2213-2600(17)30434-4

14. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62(3):237-241. doi:10.1136/thx.2006.068379

15. US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(13):1372-1377. doi:10.1001/jama.2016.2638

16. Lal S, Ferguson AD, Campbell EJ. Forced expiratory time: a simple test for airways obstruction. BMJ. 1964;1(5386):814-817. doi:10.1136/bmj.1.5386.814

17. MiravitllesM, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610. doi:10.1183/13993003.00610-2017

18. Hurley K, O’Connor GT. Serum α1-antitrypsin concentration in the diagnosis of α1-antitrypsin deficiency. JAMA. 2018;319(19):2034-2035. doi:10.1001/jama.2018.3888

19. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2016;9:CD007851. doi:10.1002/14651858.CD007851.pub3.

20. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873

21. Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as predictors of lung cancer. Chest. 2018;153 (6):1326-1335. doi:10.1016/j.chest.2018.01.049ç

22. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007;132(6):1932-1938. doi:10.1378/chest.07-1490

23. Rothnie KJ, Mullerova H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464-471. doi:10.1164/rccm.201710-2029OC

24. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138. doi:10.1056/NEJMoa0909883

25. Guerra B, Haile SR, Lamprecht B, et al; 3CIA collaboration. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Med. 2018;16(1):33. doi:10.1186/s12916-018-1013-yç

26. van Eerd EAM, Risor MB, van Rossem CR, van Schayck OCP, Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease—a qualitative analysis. BMC FamPract. 2015;16:164.doi:10.1186/s12875-015-0382-y

27. Kopsaftis Z,Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;6:CD002733. doi:10.1002/14651858.CD002733.pub3

28. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged_65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb MortalWkly Rep. 2014;63(37):822-825.

29. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest. 1994;105(5):1411-1419. doi:10.1378/chest.105.5.1411

30. Qaseem A, Wilt TJ,Weinberger SE, et al; American College of Physicians. American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191. doi:10.7326/0003-4819-155-3-201108020-00008

31. Yawn BB, Thomashaw B, Mannino DM, et al. The 2017 update to the COPD foundation COPD pocket consultant guide. Chronic Obstr Pulm Dis (Miami). 2017;4(3):177-185. doi:10.15326/jcopdf.4.3. 2017.0136

32. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(7):CD009285. doi:10.1002/14651858.CD009285.pub3

33. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;(3):CD010844. doi:10.1002/14651858.CD010844.pub2

34. Kew KM, Mavergames C,Walters JAE. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177. doi:10.1002/14651858. CD010177.pub2

35. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15-25. doi:10.1136/thoraxjnl-2014-206732

36. Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907-922. doi:10.2147/COPD.S130482

Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease Review Clinical Review & Education jama.

37. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD003794. doi:10.1002/14651858.CD003794.pub4

38. Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388. doi:10.1136/bmj.k4388

39. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;9: CD002309. doi:10.1002/14651858.CD002309.pub5

40. Albert RK, Connett J, BaileyWC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698. doi:10.1056/NEJMoa1104623

41. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(9):CD009157. doi:10.1002/14651858.CD009157.pub2

42. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181-1196. doi:10.1016/j.chest.2016.02.646

43. Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017; 49(5):1602245. doi:10.1183/13993003.02245-2016

44. WangM-T, Liou J-T, Lin CW, et al.  Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229-238. doi:10. 1001/jamainternmed.2017.7720

45. Goto T, Shimada YJ, Faridi MK, Camargo CA Jr, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33(9):1461-1468. doi:10.1007/s11606-018-4518-3

46. Lipson DA, Barnhart F, Brealey N, et al. IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med.

2018;378(18):1671-1680. doi:10.1056/NEJMoa1713901

47. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391 (10125):1076-1084. doi:10.1016/S0140-6736(18)30206-X

48. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS):a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747-758. doi:10.1016/S2213-2600(18)30327-8

49. Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. doi:10.1183/13993003.00451-2017

50. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16 (2):118-122. doi:10.1097/MCP.0b013e328334c085

51. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117-126. doi:10.1016/S2213-2600(18)30006-7

52. Magnussen H, Disse B, Rodriguez-Roisin R, et al. WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-1294. doi:10.1056/ NEJMoa1407154

53. Watz H, Tetzlaff K,Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390-398. doi:10.1016/S2213-2600(16) 00100-4

54. Chapman KR, Hurst JR, Frent S-M, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329-339. doi:10.1164/rccm.201803-0405OC

55. Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518-2533. doi:10.1007/s12325-017-0626-4

56. Aziz MIA, Tan LE,Wu DB-C, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203-3231. doi:10.2147/COPD.S173472

57. Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333-1343. doi: 10.1164/rccm.201604-0733OC

58. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11): 939-943. doi:10.1136/thx.2009.113662

59. Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi:10.1038/s41533-017-0016-z

60. Melani AS, Bonavia M, Mastropasqua E, et al. Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri (AIPO). Time required to rectify inhaler errors among experienced subjects with faulty technique. Respir Care. 2017;62(4):409-414. doi:10.4187/respcare.05117

61. Sharma G, Mahler DA,Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. hronic Obstr Pulm Dis (Miami). 2017;4(3):217-224. doi:10.15326/jcopdf.4.3.2017.0183

62. Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103-1107. doi:10.1513/AnnalsATS.201702-156PS

63. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-398. doi:10.7326/0003-4819-93-3-391

64. Medical Research CouncilWorking Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research CouncilWorking Party. Lancet. 1981;1(8222):681-686.

65. Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive ulmonary disease patients. Am J Respir Crit Care Med. 2003;168(9):1034-1042. doi:10.1164/rccm.200212-1525OC

66. Albert RK, Au DH, Blackford AL, et al; Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617-1627. doi:10.1056/NEJMoa1604344

67. Rochester CL, Vogiatzis I, Holland AE, et al; ATS/ERS Task Force on Policy in Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373-1386. doi:10.1164/rccm.201510-1966ST 68. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793. doi:10. 1002/14651858.CD003793.pub3

69. Nishi SPE, ZhangW, Kuo Y-F, Sharma G. Pulmonary rehabilitation utilization in older adults with chronic obstructive pulmonary disease, 2003 to 2012. J Cardiopulm Rehabil Prev. 2016;36(5):375-382. doi:10.1097/HCR.0000000000000194

70. Ryrso CK, Godtfredsen NS, Kofod LM, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018;18(1):154. doi:10.1186/s12890-018-0718-1

71. Wedzicha JA, MiravitllesM, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016

72. Walters JA, Tan DJ, White CJ,Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3:CD006897. doi:10.1002/14651858.CD006897.pub4

73. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10:CD010257. doi:10.1002/14651858.CD010257.pub2

74. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410-419. doi:10.1183/13993003.01359-2015

75. Rocha A, Arbex FF, Sperandio PA, et al. Excess ventilation in chronic obstructive pulmonary disease-heart failure overlap: implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med. 2017;196(10):1264-1274. doi:10.1164/rccm.201704-0675OC

76. Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259-270. doi:10.5664/jcsm.4540

77. Yohannes AM, Kaplan A, Hanania NA. Anxiety and depression in chronic obstructive pulmonary disease: recognition and management. Cleve Clin J Med. 2018;85(2)(suppl 1):S11-S18. doi:10.3949/

ccjm.85.s1.03

78. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: ameta-analysis. J Gen Intern Med. 2011;26(10):1175-1182. doi:10.1007/s11606-011-1704-y

79. Maltais F, Decramer M, Casaburi R, et al; ATS/ERS Ad Hoc Committee on Limb Muscle Dysfunction in COPD. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15-e62. doi:10.1164/rccm.201402-0373ST

80. Bon J, Fuhrman CR,Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183(7):885-890. doi:10. 1164/rccm.201004-0666OC

81. Rennard SI, Calverley PMA, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-18

82. Munoz-Esquerre M, Diez-Ferrer M, Monton C, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16-21. doi:10.1016/j.pupt.2014.10.002

83. Watz H, Bagul N, Rabe KF, et al. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:813-822. doi:10.2147/COPD.S154012

84. Uzun S, Djamin RS, Kluytmans JAJW, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361-368. doi:10.1016/S2213-2600 (14)70019-0

85. Devereux G, Cotton S, Fielding S, et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA. 2018;320(15):1548-1559. doi:10.1001/jama.2018.14432

86. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7):CD001287. doi:10.1002/14651858.CD001287.pub5

87. Kohnlein T, WindischW, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014;2(9):698-705. doi:10.1016/S2213-2600 (14)70153-5

88. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177-2186. doi:10.1001/jama.2017.4451

89. Fishman A, Martinez F, Naunheim K, et al; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059-2073. doi:10.1056/NEJMoa030287

90. Criner GJ, Sue R,Wright S, et al; LIBERATE Study Group. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151-1164. doi:10.1164/rccm.201803-0590OC.